All AbMole products are for research use only, cannot be used for human consumption.
AZD5582 is an IAP antagonist that can be effectively combined with bir3 domains of cIAP1, cIAP2, and XIAP, IC50 The values are 15, 21, 15 nM, respectively. AZD5582 Induces apoptosis.
| Molecular Weight | 1015.29 |
| Formula | C58H78N8O8 |
| CAS Number | 1258392-53-8 |
| Solubility (25°C) | DMSO ≥ 20 mg/mL |
| Storage | 2-8°C, protect from light, sealed |
| Related IAP Products |
|---|
| AT-406
Xevinapant (Debio1143,AT-406, SM-406) is a potentially first-in-class, highly potent oral antagonist of inhibitor of apoptosis protein (IAP), which not only promotes cancer cell death by inhibiting IAP, but also It can enhance the anti-tumor immune response by inhibiting IAP. |
| GDC-0152
GDC-0152 is a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins with potential antineoplastic activity. |
| Birinapant
Birinapant (TL32711) is a bivalent Smac analogue, which is a potent antagonist of XIAP and cIAP1 with Kd values of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces autoubiquitination and proteasome degradation of cIAP1 and cIAP2 in intact cells, resulting in the formation of RIPK1: Caspase-8 complex, which activates and induces tumor cell death. |
| BV6
BV6 is a small molecule Smac analog that antagonizes cIAP1 and XIAP. |
| LCL161
LCL161 is an orally bioavailable SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
